Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States.

Farcet MR, Karbiener M, Rabel PO, Schirmer A, Ilk R, Kreil TR.

Vaccine. 2019 May 27;37(24):3151-3153. doi: 10.1016/j.vaccine.2019.04.022. Epub 2019 May 3.

2.

Secondary structure of DNA released from purified capsids of human parvovirus B19 under moderate denaturing conditions.

Matz B, Kupfer B, Kallies R, Külshammer M, Flötenmeyer M, Kreil TR, Eis-Hübinger AM.

J Gen Virol. 2019 May;100(5):812-827. doi: 10.1099/jgv.0.001253. Epub 2019 Mar 29.

PMID:
30924765
3.

Continuous Solvent/Detergent Virus Inactivation Using a Packed-Bed Reactor.

Martins DL, Sencar J, Hammerschmidt N, Tille B, Kinderman J, Kreil TR, Jungbauer A.

Biotechnol J. 2019 Aug;14(8):e1800646. doi: 10.1002/biot.201800646. Epub 2019 Apr 23.

PMID:
30810288
4.

Continued use of poliovirus after eradication: hyper-attenuated strains as a safe alternative for release testing of human immunoglobulins.

Farcet MR, Modrof J, Rabel PO, Schirmer A, Macadam AJ, Fox H, Minor PD, Kreil TR.

Transfusion. 2018 Dec;58 Suppl 3:3084-3089. doi: 10.1111/trf.15048.

PMID:
30536436
5.

Immunoglobulins and virus antibody titers: of past needs, current requirements, and future options.

Kreil TR, Farcet MR.

Transfusion. 2018 Dec;58 Suppl 3:3090-3095. doi: 10.1111/trf.15016. Review.

PMID:
30536431
6.

Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.

Ma J, Kreil TR.

PDA J Pharm Sci Technol. 2018 Sep-Oct;72(5):511-515. doi: 10.5731/pdajpst.2018.009175. Epub 2018 Jul 20.

PMID:
30030359
7.

Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.

Kreil TR, Roush D.

PDA J Pharm Sci Technol. 2018 Sep-Oct;72(5):470-478. doi: 10.5731/pdajpst.2018.009118. Epub 2018 Jul 20.

PMID:
30030356
8.

Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.

Roush D, Kreil TR.

PDA J Pharm Sci Technol. 2018 Sep-Oct;72(5):479-487. doi: 10.5731/pdajpst.2018.009126. Epub 2018 Jul 20.

PMID:
30030354
9.

Characterization of source plasma from self-identified vaccinated or convalescent donors during the 2009 H1N1 pandemic.

Khalenkov A, He Y, Reed JL, Kreil TR, McVey J, Norton M, Scott J, Scott DE.

Transfusion. 2018 May;58(5):1108-1116. doi: 10.1111/trf.14530. Epub 2018 Feb 15.

PMID:
29446442
10.

Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins: Is an Increase by Revaccination of Plasma Donors Possible?

Modrof J, Tille B, Farcet MR, McVey J, Schreiner JA, Borders CM, Gudino M, Fitzgerald P, Simon TL, Kreil TR.

J Infect Dis. 2017 Nov 15;216(8):977-980. doi: 10.1093/infdis/jix428.

PMID:
28968738
11.

A nonenveloped virus with a lipid envelope: hepatitis A virus as used in virus-reduction studies.

Kapsch AM, Farcet MR, Antoine G, Kreil TR.

Transfusion. 2017 Jun;57(6):1433-1439. doi: 10.1111/trf.14091. Epub 2017 Mar 28.

PMID:
28370030
12.

Zika virus is not thermostable: very effective virus inactivation during heat treatment (pasteurization) of human serum albumin.

Farcet MR, Kreil TR.

Transfusion. 2017 Mar;57(3pt2):797-801. doi: 10.1111/trf.13953. Epub 2016 Dec 17.

PMID:
27987206
13.

Virus Filtration and Flow Variation: An Approach To Evaluate Any Potential Impact on Virus Retention.

Wieser A, Berting A, Medek C, Poelsler G, Kreil TR; Global Pathogen Safety, Baxalta (now a part of Shire).

PDA J Pharm Sci Technol. 2016 Jul-Aug;70(4):325-31. doi: 10.5731/pdajpst.2015.006346. Epub 2016 Mar 28.

PMID:
27020648
14.

Meeting Report: 2015 PDA Virus & TSE Safety Forum.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Kreil TR, Ruffing M, Ruiz S, Scott D, Silvester G.

PDA J Pharm Sci Technol. 2016 Mar-Apr;70(2):177-88. doi: 10.5731/pdajpst.2016.006569. Epub 2016 Mar 28.

PMID:
27020643
15.

Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.

Beck Y, Fritz R, Orlinger K, Kiermayr S, Ilk R, Portsmouth D, Pöllabauer EM, Löw-Baselli A, Hessel A, Kölch D, Howard MK, Barrett PN, Kreil TR.

J Virol. 2015 Dec 9;90(4):1964-72. doi: 10.1128/JVI.02985-15. Print 2016 Feb 15.

16.

Blood transmission studies of prion infectivity in the squirrel monkey (Saimiri sciureus): the Baxter study.

Ritchie DL, Gibson SV, Abee CR, Kreil TR, Ironside JW, Brown P.

Transfusion. 2016 Mar;56(3):712-21. doi: 10.1111/trf.13422. Epub 2015 Nov 23.

17.

Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.

Farcet MR, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, Unger U, Modrof J, Kreil TR.

Transfusion. 2016 Feb;56(2):383-91. doi: 10.1111/trf.13343. Epub 2015 Sep 24.

PMID:
26399175
18.

Measuring the effectiveness of gaseous virus disinfectants.

Knotzer S, Kindermann J, Modrof J, Kreil TR.

Biologicals. 2015 Nov;43(6):519-23. doi: 10.1016/j.biologicals.2015.06.002. Epub 2015 Aug 7.

PMID:
26260690
19.

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients.

Fritz R, Hetzelt N, Ilk R, Hohenadl C, van der Velden MV, Aichinger G, Portsmouth D, Kistner O, Howard MK, Barrett PN, Kreil TR.

Open Forum Infect Dis. 2014 Aug 25;1(2):ofu072. doi: 10.1093/ofid/ofu072. eCollection 2014 Sep.

20.

Treatment of Ebola virus infection with antibodies from reconvalescent donors.

Kreil TR.

Emerg Infect Dis. 2015 Mar;21(3):521-3. doi: 10.3201/eid2103.141838.

21.

Reflections on the emergence of chikungunya virus in the United States: time to revisit a successful paradigm for the safety of blood-derived therapies.

Farrugia A, Kreil TR.

Transfusion. 2015 Jan;55(1):224-6. doi: 10.1111/trf.12933. No abstract available.

PMID:
25582241
22.

Parallel evaluation of broad virus detection methods.

Modrof J, Berting A, Kreil TR.

PDA J Pharm Sci Technol. 2014 Nov-Dec;68(6):572-8. doi: 10.5731/pdajpst.2014.01014.

PMID:
25475631
23.

The evolution of down-scale virus filtration equipment for virus clearance studies.

Wieser A, Berting A, Medek C, Poelsler G, Kreil TR.

Biotechnol Bioeng. 2015 Mar;112(3):633-7. doi: 10.1002/bit.25452. Epub 2014 Nov 19.

PMID:
25220795
24.

Meeting report-workshop on spike characterizations and virus removal by filtration: trends and new developments.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Hubbard BR, Kreil TR, Ruffing M, Ruiz S, Scott D, Silvester G.

PDA J Pharm Sci Technol. 2014 May-Jun;68(3):215-20. doi: 10.5731/pdajpst.2014.00981.

PMID:
25188344
25.

Meeting Report: 2013 PDA Virus & TSE Safety Forum.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Hubbard BR, Kreil TR, Ruffing M, Ruiz S, Scott D, Silvester G.

PDA J Pharm Sci Technol. 2014 May-Jun;68(3):193-214. doi: 10.5731/pdajpst.2014.00980.

PMID:
25188343
26.

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice.

Hohenadl C, Wodal W, Kerschbaum A, Fritz R, Howard MK, Farcet MR, Portsmouth D, McVey JK, Baker DA, Ehrlich HJ, Barrett PN, Kreil TR.

Virol J. 2014 Apr 16;11:70. doi: 10.1186/1743-422X-11-70.

27.

Reduction of spiked porcine circovirus during the manufacture of a Vero cell-derived vaccine.

Lackner C, Leydold SM, Modrof J, Farcet MR, Grillberger L, Schäfer B, Anderle H, Kreil TR.

Vaccine. 2014 Apr 11;32(18):2056-61. doi: 10.1016/j.vaccine.2014.02.011. Epub 2014 Feb 20.

PMID:
24560672
28.

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

Hessel A, Savidis-Dacho H, Coulibaly S, Portsmouth D, Kreil TR, Crowe BA, Schwendinger MG, Pilz A, Barrett PN, Falkner FG, Schäfer B.

PLoS One. 2014 Feb 11;9(2):e88340. doi: 10.1371/journal.pone.0088340. eCollection 2014.

29.

Evaluation of different serological diagnostic methods for tick-borne encephalitis virus: enzyme-linked immunosorbent, immunofluorescence, and neutralization assay.

Litzba N, Zelená H, Kreil TR, Niklasson B, Kühlmann-Rabens I, Remoli ME, Niedrig M.

Vector Borne Zoonotic Dis. 2014 Feb;14(2):149-59. doi: 10.1089/vbz.2012.1287. Epub 2013 Dec 20.

PMID:
24359414
30.

Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G.

J Infect Dis. 2014 Jan 1;209(1):12-23. doi: 10.1093/infdis/jit498. Epub 2013 Sep 16.

PMID:
24041789
31.

In reply.

Kreil TR, Farcet MR.

Transfusion. 2013 Sep;53(9):2104-5. doi: 10.1111/trf.12296. No abstract available.

PMID:
24015940
32.

Meeting report--workshop on virus removal by filtration: trends and new developments.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Kreil TR, Robertson JS, Ruffing M, Ruiz S.

PDA J Pharm Sci Technol. 2013 Mar-Apr;67(2):98-104. doi: 10.5731/pdajpst.2013.00907.

PMID:
23569071
33.

Meeting Report: PDA Virus and TSE Safety Forum.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Kreil TR, Robertson JS, Ruffing M, Ruiz S.

PDA J Pharm Sci Technol. 2013 Mar-Apr;67(2):81-97. doi: 10.5731/pdajpst.2013.00906. Review.

PMID:
23569070
34.

Tick-borne encephalitis virus vaccine as additional alternative neoantigen for the clinical immunologist's toolbox.

Seidel MG, Planitzer CB, Kreil TR, Förster-Waldl E.

J Allergy Clin Immunol. 2013 Feb;131(2):617. doi: 10.1016/j.jaci.2012.11.029. Epub 2012 Dec 28. No abstract available.

PMID:
23273959
35.

Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.

Cai K, Gröner A, Dichtelmüller HO, Fabbrizzi F, Flechsig E, Gajardo R, von Hoegen I, Jorquera JI, Kempf C, Kreil TR, Lee DC, Moscardini M, Pölsler G, Roth NJ.

Transfusion. 2013 Sep;53(9):1894-905. doi: 10.1111/trf.12050. Epub 2012 Dec 17.

PMID:
23252676
36.

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.

Sabarth N, Savidis-Dacho H, Schwendinger MG, Brühl P, Portsmouth D, Crowe BA, Kistner O, Barrett PN, Kreil TR, Howard MK.

Vaccine. 2012 Aug 10;30(37):5533-40. doi: 10.1016/j.vaccine.2012.06.043. Epub 2012 Jun 29.

PMID:
22749797
37.

A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.

Wodal W, Falkner FG, Kerschbaum A, Gaiswinkler C, Fritz R, Kiermayr S, Portsmouth D, Savidis-Dacho H, Coulibaly S, Piskernik C, Hohenadl C, Howard MK, Kistner O, Barrett PN, Kreil TR.

Vaccine. 2012 Jun 29;30(31):4625-31. doi: 10.1016/j.vaccine.2012.04.102. Epub 2012 May 10.

PMID:
22580355
38.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
39.

Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.

Rabel PO, Planitzer CB, Farcet MR, Kreil TR.

Clin Vaccine Immunol. 2012 Apr;19(4):623-5. doi: 10.1128/CVI.05705-11. Epub 2012 Feb 29.

40.

Chikungunya virus and the safety of plasma products.

Leydold SM, Farcet MR, Kindermann J, Modrof J, Pölsler G, Berting A, Howard MK, Barrett PN, Kreil TR.

Transfusion. 2012 Oct;52(10):2122-30. doi: 10.1111/j.1537-2995.2012.03565.x. Epub 2012 Feb 17.

PMID:
22339168
41.

Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes.

Fritz R, Orlinger KK, Hofmeister Y, Janecki K, Traweger A, Perez-Burgos L, Barrett PN, Kreil TR.

Vaccine. 2012 Feb 1;30(6):1165-9. doi: 10.1016/j.vaccine.2011.12.013. Epub 2011 Dec 14.

PMID:
22178103
42.

Selection of recombinant MVA by rescue of the essential D4R gene.

Ricci PS, Schäfer B, Kreil TR, Falkner FG, Holzer GW.

Virol J. 2011 Dec 12;8:529. doi: 10.1186/1743-422X-8-529.

43.

A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies.

Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR.

J Infect Dis. 2012 Jan 1;205(1):28-34. doi: 10.1093/infdis/jir711. Epub 2011 Nov 16.

PMID:
22090447
44.

Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.

Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN.

Vaccine. 2011 Nov 21;29(50):9376-84. doi: 10.1016/j.vaccine.2011.09.125. Epub 2011 Oct 12.

PMID:
22001875
45.

Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza.

Kreil TR, Mc Vey JK, Lei LS, Camacho L, Wodal W, Kerschbaum A, Segura E, Vandamme E, Gavit P, Ehrlich HJ, Barrett PN, Baker DA.

Transfusion. 2012 Apr;52(4):803-9. doi: 10.1111/j.1537-2995.2011.03347.x. Epub 2011 Oct 7.

PMID:
21981280
46.

Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.

Schäfer B, Holzer GW, Joachimsthaler A, Coulibaly S, Schwendinger M, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2011;6(9):e24505. doi: 10.1371/journal.pone.0024505. Epub 2011 Sep 9.

47.

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model.

Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN.

PLoS One. 2011;6(8):e23791. doi: 10.1371/journal.pone.0023791. Epub 2011 Aug 18.

48.

Inactivation of hepatitis A variants during heat treatment (pasteurization) of human serum albumin.

Farcet MR, Kindermann J, Modrof J, Kreil TR.

Transfusion. 2012 Jan;52(1):181-7. doi: 10.1111/j.1537-2995.2011.03251.x. Epub 2011 Jul 25.

PMID:
21790623
49.

Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.

Planitzer CB, Saemann MD, Gajek H, Farcet MR, Kreil TR.

Transplantation. 2011 Aug 15;92(3):267-70. doi: 10.1097/TP.0b013e318224115e.

PMID:
21659947
50.

A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.

Orlinger KK, Hofmeister Y, Fritz R, Holzer GW, Falkner FG, Unger B, Loew-Baselli A, Poellabauer EM, Ehrlich HJ, Barrett PN, Kreil TR.

J Infect Dis. 2011 Jun 1;203(11):1556-64. doi: 10.1093/infdis/jir122.

PMID:
21592984

Supplemental Content

Loading ...
Support Center